Osteoblast as a target of anti-osteoporotic treatment

References

• Chatakun P, Núñez-Toldrà R, Díaz López EJ, et al. The effect of five proteins on stem cells used for osteoblast differentiation and proliferation: a current review of the literature. Cell Mol Life Sci. 2014 Jan;71(1):113–142.
   PubMed Web of Science ®Google Scholar
• Hunter GK. Role of osteopontin in modulation of hydroxyapatite formation. Calcif Tissue Int. 2013 Oct;93(4):348–354.
   PubMed Web of Science ®Google Scholar
• Cantatore FP, Corrado A, Grano M, et al. Osteocalcin synthesis by human osteoblasts from normal and osteoarthritic bone after vitamin D3 stimulation. Clin Rheumatol. 2004;23:490–495.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhang X. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review). Mol Med Rep. 2015 May;11(5):3212–3218.
   PubMed Web of Science ®Google Scholar
• Langdahl B, Ferrari S, Dempster DW. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2016 Dec;8(6):225–235.
   PubMed Web of Science ®Google Scholar
• Spencer GJ, McGrath CJ, Genever PG. Current perspectives on NMDA-type glutamate signalling in bone. Int J Biochem Cell Biol. 2007;39(6):1089–1104.
   PubMed Web of Science ®Google Scholar
• Marie PJ. Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies. Cell Mol Life Sci. 2015 Apr;72(7):1347–1361.
   PubMed Web of Science ®Google Scholar
• Corrado A, Neve A, Macchiarola A, et al. RANKL/OPG ratio and DKK-1 expression in primary osteoblastic cultures from osteoarthritic and osteoporotic subjects. J Rheumatol. 2013 May;40(5):684–694.
   PubMed Web of Science ®Google Scholar
• Shi Z, Zhou H, Pan B, et al. Effectiveness of teriparatide on fracture healing: a systematic review and meta-analysis. PLoS One. 2016 Dec 20;11(12):e0168691.
   PubMed Web of Science ®Google Scholar
• Stewart AF. Hyperparathyroidism, humoral hypercalcemia of malignancy, and the anabolic actions of parathyroid hormone and parathyroid hormone-related protein on the skeleton. J Bone Miner Res. 2002;17:758–762.
   PubMed Web of Science ®Google Scholar
• Lombardi G, Di Somma C, Rubino M, et al. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics. J Endocrinol Invest. 2011;34(7 Suppl):18–22.
   Google Scholar
• Krishnan V, Moore TL, Ma YL, et al. Parathyroid hormone bone anabolic action requiresCbfa1/Runx2-dependent signaling. Mol Endocrinol. 2003;17:423–435.
   PubMed Web of Science ®Google Scholar
• Shen R, Wang X, Drissi H, et al. Cyclin D1-Cdk4 induce Runx2 ubiquitination and degradation. J Biol Chem. 2006;281(24):16347–16353.
   PubMed Web of Science ®Google Scholar
• Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995;136:3632–3638.
   PubMed Web of Science ®Google Scholar
• Ardura JA, Portal-Núñez S, Castelbón-Calvo I, et al. Parathyroid hormone-related protein protects osteoblastic cells from oxidative stress by activation of MKP1 phosphatase. J Cell Physiol. 2017 Apr;232(4):785–796.
   PubMed Web of Science ®Google Scholar
• Swarthout JT, Doggett TA, Lemker JL, et al. Stimulation of extracellular signal regulated kinases and proliferation in rat osteoblastic cells by parathyroid hormone is protein kinase C dependent. J Biol Chem. 2001;276:7586–7592.
   PubMed Web of Science ®Google Scholar
• Osagie-Clouard L, Sanghani A, Coathup M, et al. Parathyroid hormone 1-34 and skeletal anabolic action: the use of parathyroid hormone in bone formation. Bone Joint Res. 2017 Jan;6(1):14–21.
   PubMed Web of Science ®Google Scholar
• Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 2009;104:439–446.
   Web of Science ®Google Scholar
• Stanislaus D, Yang X, Liang JD, et al. In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1-34) fragment. Bone. 2000;27:209–218.
   PubMed Web of Science ®Google Scholar
• Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem. 2003;278:50259–50272.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Zhou H, Cosman F, et al. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res. 2007;22:495–502.
   PubMed Web of Science ®Google Scholar
• Watson P, Lazowski D, Han V, et al. Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone. 1995;16:357–365.
   PubMed Web of Science ®Google Scholar
• Bikle DD, Sakata T, Leary C, et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res. 2002;17:1570–1578.
   PubMed Web of Science ®Google Scholar
• Miyakoshi N, Kasukawa Y, Linkhart TA, et al. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology. 2001;142:4349–4356.
   PubMed Web of Science ®Google Scholar
• Hurley MM, Tetradis S, Huang YF, et al. Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells. J Bone Miner Res. 1999;14:776–783.
   PubMed Web of Science ®Google Scholar
• Hurley MM, Okada Y, Xiao L, et al. Impaired bone anabolic response to parathyroid hormone in Fgf2 /- and Fgf2± mice. Biochem Biophys Res Commun. 2006;24:989–994.
   Web of Science ®Google Scholar
• Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005;37:48–58.
   Web of Science ®Google Scholar
• O’Brien CA, Plotkin LI, Galli C, et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008;13:3(8).
   Google Scholar
• Fermor B, Skerry TM. PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. J Bone Miner Res. 1995;10:1935–1943.
   PubMed Web of Science ®Google Scholar
• Guo J, Liu M, Yang D, et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab. 2010;1:161–171.
   Web of Science ®Google Scholar
• Suzuki A, Ozono K, Kubota T, et al. PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3β in osteoblastic Saos-2 cells. J Cell Biochem. 2008;104:304–317.
   PubMed Web of Science ®Google Scholar
• Tobimatsu T, Kaji H, Sowa H, et al. Parathyroid hormone increases β-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology. 2006;147:2583–2590.
   PubMed Web of Science ®Google Scholar
• Wan M, Yang C, Li J, et al. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev. 2008;22:2968–2979.
   PubMed Web of Science ®Google Scholar
• Maruotti N, Corrado A, Neve A, et al. Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol. 2012 Jul;68(7):1013–1018.
   PubMed Web of Science ®Google Scholar
• Monroe DG, McGee-Lawrence ME, Oursler MJ, et al. Update on Wnt signaling in bone cell biology and bone disease. Gene. 2012;492:1–18.
   PubMed Web of Science ®Google Scholar
• Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108:837–847.
   PubMed Web of Science ®Google Scholar
• Gaur T, Lengner CJ, Hovhannisyan H, et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem. 2005;280:33132–33140.
   PubMed Web of Science ®Google Scholar
• Liu F, Kohlmeier S, Wang CY. Wntsignaling and skeletal development. Cell Signal. 2008;20:999–1009.
   PubMed Web of Science ®Google Scholar
• Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002;11:17–29.
   Web of Science ®Google Scholar
• Lerner UH, Ohlsson C. The WNT system: background and its role in bone. J Intern Med. 2015 Jun;277(6):630–649.
   PubMed Web of Science ®Google Scholar
• Malinauskas T, Jones EY. Extracellular modulators of Wnt signalling. Curr Opin Struct Biol. 2014 Dec;29:77–84.
   PubMed Web of Science ®Google Scholar
• Karner CM, Long F. Wnt signaling and cellular metabolism in osteoblasts. Cell Mol Life Sci. 2017;74:1649–1657.
   PubMed Web of Science ®Google Scholar
• Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene. 2006;25:7469–7481.
   PubMed Web of Science ®Google Scholar
• Little RD, Recker RR, Johnson ML. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;347(12):943–944.
   PubMed Web of Science ®Google Scholar
• Cui Y, Niziolek PJ, MacDonald BT, et al. Lrp5 functions in bone to regulate bone mass. Nat Med. 2011;17(6):684–691.
   PubMed Web of Science ®Google Scholar
• Babij P, Zhao W, Small C, et al. High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res. 2006;18(6):960–974.
   Web of Science ®Google Scholar
• Balemans W, van Hul W. The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. Endocrinology. 2007;148:2622–2629.
   PubMed Web of Science ®Google Scholar
• Kato M, Patel MS, Levasseur R, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol. 2002;157(2):303–314.
   PubMed Web of Science ®Google Scholar
• Song L, Liu M, Ono N, et al. Loss of wnt/beta-catenin signaling causes cell fate shift of preo-steoblasts from osteoblasts to adipocytes. J Bone Miner Res. 2012;27(11):2344–2358.
   PubMed Web of Science ®Google Scholar
• Hill TP, Später D, Taketo MM, et al. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell. 2005;8(5):727–738. PubMed PMID: 15866163.
   PubMed Web of Science ®Google Scholar
• Bennett CN, Longo KA, Wright WS, et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci USA. 2005 1;102(9):3324–3329.
   PubMed Web of Science ®Google Scholar
• Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23(6):860–869.
   PubMed Web of Science ®Google Scholar
• Morvan F, Boulukos K, Clément-Lacroix P, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res. 2006;21(6):934–945.
   PubMed Web of Science ®Google Scholar
• Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578–588.
   PubMed Web of Science ®Google Scholar
• McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014 30;370(5):412–420.
   PubMed Web of Science ®Google Scholar
• Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016 20;375(16):1532–1543.
   PubMed Web of Science ®Google Scholar
• Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015 Feb;30(2):216–224.
   PubMed Web of Science ®Google Scholar
• Glantschnig H, Hampton RA, Lu P, et al. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem. 2010 7;285(51):40135–40147.
   PubMed Web of Science ®Google Scholar
• Sykiotis A, Papaioannou G, Mavropoulos J, et al. Markers of inflammation after zoledronic acid redosing. J Bone MinerMetab. 2014;32(1):72–77.
   PubMed Web of Science ®Google Scholar
• Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphosphonates. Joint Bone Spine. 2007;74(1):32–38.
   PubMed Web of Science ®Google Scholar
• Iannitti T, Rosini S, Lodi D, et al. Bisphosphonates: focus on inflammation and bone loss. Am J Ther. 2012;19(3):228–246.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Maruotti N, Nico B, et al. Clodronate inhibits angiogenesis in vitro and in vivo. Oncol Rep. 2008;19(5):1109–1112.
   PubMed Web of Science ®Google Scholar
• Sahni M, Guenther HL, Fleisch H, et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 1993;91:2004–2011.
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Akatsu T, Katayama Y, et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone. 1996;18:9–14.
   PubMed Web of Science ®Google Scholar
• Evans CE, Braidman I. Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner. 1994;26:95–107.
   PubMedGoogle Scholar
• Fromigue O, Body JJ. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest. 2002;25:539–546.
   PubMed Web of Science ®Google Scholar
• Tsuchimoto M, Azuma Y, Higuchi O, et al. Alendronate modulates osteogenesis of human osteoblastic cell in vitro. Jpn J Pharmacol. 1994;66:25–33.
   PubMedGoogle Scholar
• Corrado A, Cantatore FP, Grano M, et al. Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects. Clin Rheumatol. 2005;24(5):527–534.
   PubMed Web of Science ®Google Scholar
• Corrado A, Neve A, Maruotti N, et al. Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures. Clin Exp Rheumatol. 2010;28(6):873–879.
   PubMed Web of Science ®Google Scholar
• Viereck V, Emons G, Lauck V, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun. 2002;291:680–686.
   PubMed Web of Science ®Google Scholar
• Greiner S, Kadow-Romacker A, Lubberstedt M, et al. The effect of zoledronic acid incorporated in a poly(D, L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res. 2007;80:769–775.
   Web of Science ®Google Scholar
• Pan B, Farrugia AN, To LB, et al. The nitrogen containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res. 2004;19:147–154.
   PubMed Web of Science ®Google Scholar
• Im G, Qureshi SA, Kenney J, et al. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials. 2004;25:4105–4115.
   PubMed Web of Science ®Google Scholar
• Sun J, Song F, Zhang W, et al. Effects of alendronate on human osteoblast-like MG63 cells and matrix metalloproteinases. Arch Oral Biol. 2012;57(6):728–736.
   PubMed Web of Science ®Google Scholar
• Komatsu K, Shimada A, Shibata T, et al. Alendronate promotes bone formation by inhibiting protein prenylation in osteoblasts in rat tooth replantation model. J Endocrinol. 2013;219(2):145–158.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Pedrazzoni M, Negri G, et al. Biphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone. 1998;22:455–461.
   PubMed Web of Science ®Google Scholar
• Kim HK, Kim JH, Abbas AA, et al. Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study. Clin Orthop Relat Res. 2009;467:3121–3128.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Yang HJ, Feng J, et al. Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res. 2009;37:407–416.
   PubMed Web of Science ®Google Scholar
• Lindtner RA, Tiaden AN, Genelin K, et al. Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss. Osteoporos Int. 2014;25(3):1151–1161.
   PubMed Web of Science ®Google Scholar
• von Knoch F, Jaquiery C, Kowalsky M, et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials. 2005;26(34):6941–6949.
   PubMed Web of Science ®Google Scholar
• Ribeiro V, Garcia M, Oliveira R, et al. Bisphosphonates induce the osteogenic gene expression in co-cultured human endothelial and mesenchymal stem cells. J Cell MolMed. 2014;18(1):27–37.
   PubMed Web of Science ®Google Scholar
• Mathov I, Plotkin LI, Sgarlata CL, et al. Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J Bone Miner Res. 2001;16:2050–2056.
   PubMed Web of Science ®Google Scholar
• Idris AI, Rojas J, Greig IR, et al. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int. 2008;82:191–201.
   PubMed Web of Science ®Google Scholar
• Manzano-Moreno FJ, Ramos-Torrecillas J, De Luna-Bertos E, et al. High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis. J Craniomaxillofac Surg. 2015;43(3):396–401.
   PubMed Web of Science ®Google Scholar
• Orriss IR, Key ML, Colston KW, et al. Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem. 2009;106:109–118.
   PubMed Web of Science ®Google Scholar
• Itoh F, Aoyagi S, Furihata-Komatsu H, et al. Clodronate stimulates osteoblast differentiation in ST2 and MC3T3-E1 cells and rat organ cultures. Eur J Pharmacol. 2003;477:9–16.
   PubMed Web of Science ®Google Scholar
• Abe Y, Kawakami A, Nakashima T, et al. Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cells. J Lab Clin Med. 2000;136(5):344–354.
   PubMed Web of Science ®Google Scholar
• Plotkin LI, Weinstein RS, Parfitt AM, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363–1374.
   PubMed Web of Science ®Google Scholar
• Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone. 2011;49:50–55.
   PubMed Web of Science ®Google Scholar
• Lezcano V, Bellido T, Plotkin LI, et al. Osteoblastic protein tyrosine phosphatases inhibition and connexin 43 phosphorylation by alendronate. Exp Cell Res. 2014 15;324(1):30–39.
   PubMed Web of Science ®Google Scholar
• Reinholz GG, Getz B, Pederson L, et al. Bisphosphonates directly regulate cell proliferation, differentiation and gene expression in human osteoblasts. Cancer Res. 2000;60:6001–6007.
   PubMed Web of Science ®Google Scholar
• Basso FG, Silveira-Turrioni AP, Hebling J, et al. Acid inhibits human osteoblast activities. Gerontology. 2013;59(6):534–541.
   PubMed Web of Science ®Google Scholar
• Forte L, Torricelli P, Boanini E, et al. Antiresorptive and anti-angiogenetic octacalcium phosphate functionalized with bisphosphonates: an in vitro tri-culture study. Acta Biomater. 2017;54:419–428.
   PubMed Web of Science ®Google Scholar